ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

evolocumab

Also written as “Evolocumab”, “Evolocumab AI/pen” and “Evolocumab Drug Substance A (Test)”.

Its studies are mostly in Hypercholesterolemia · Hyperlipidemias · Dyslipidemias · Coronary Artery Disease · Homozygous Familial Hypercholesterolemia, led by 4 companies.

Drug pageEvolocumab: every studyAll 108 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Jan 3, 201845 company-led studies, 2 open or runningNext primary completion: May 29, 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Amgen422 open or runningphase 4since Jan 3, 2018May 27, 2010May 29, 2027phase 4 · NCT05284747
ECRI bvits history only10 open or runningphase 4since Feb 12, 2019Feb 12, 2019none ahead
Hamad Medicalits history only10 open or runningphase 4since Oct 10, 2022Oct 10, 2022none ahead
Hoffmann-La Rocheits history only10 open or runningphase 2since Nov 7, 2017Nov 7, 2017none ahead

Also a collaborator on its studies: GE Healthcare and HeartFlow.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Amgen only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 28 studies since May 27, 2010.

  1. Jan 20, 2016Phase 3 study in Diabetes MellitusNCT02662569 · 986 enrolled · United States, Argentina, Brazil and more
  2. Mar 8, 2016Phase 3 study in DyslipidemiasNCT02729025 · 129 enrolled · United States, Canada, Netherlands
  3. Apr 12, 2016Phase 3 study in HypercholesterolemiaNCT02739984 · 424 enrolled · United States, Belgium, Canada and more
  4. Jun 13, 2016Phase 3 study in DyslipidemiasNCT02833844 · 467 enrolled · United States, Australia, Belgium and more
  5. Jul 20, 2016Phase 3 study in DyslipidemiasNCT02867813 · 5,035 enrolled · United States, Czechia, Hungary and more
  6. Mar 10, 2017Phase 3 study in DyslipidemiasNCT03080935 · 1,600 enrolled · Belgium, Denmark, France and more
  7. Jan 3, 2018Phase 4 study in HypercholesterolemiaNCT03403374 · 30 enrolled · India
  8. Jan 18, 2018Phase 3 study in HypercholesterolemiaNCT03433755 · 259 enrolled · China
  9. Jun 18, 2018Phase 3 study in Coronary Artery DiseaseNCT03570697 · 164 enrolled · United States, Australia, Czechia and more
  10. Mar 11, 2019Phase 3 study in Coronary DiseaseNCT03872401 · 12,301 enrolled · United States, Argentina, Australia and more
  11. Mar 9, 2022Phase 4 study in Cardiovascular DiseasesNCT05284747 · 6,019 enrolled · United States, Brazil, Sweden
  12. Feb 12, 2026Phase 1 study in Healthy ParticipantsNCT07422285 · 405 enrolled · United States
  13. Apr 16, 2026Phase 1 study in Healthy ParticipantsNCT07545226 · 405 enrolled · United States
  14. Aug 31, 2026Phase 4 study in Coronary Artery DiseaseNCT07803679 · 308 planned

Ahead

  1. May 29, 2027Primary completion: phase 4 study in Cardiovascular DiseasesNCT05284747
  2. Apr 30, 2029Primary completion: phase 4 study in Coronary Artery DiseaseNCT07803679

TargetBeta

PCSK9 →read by rule
“A human immunoglobulin G2 (IgG2) monoclonal antibody directed against human proprotein convertase subtilisin/kexin type 9 (PCSK9), that can be used in the treatment of hypercholesterolemia”NCIt, by rule
“Subtilisin/kexin type 9 inhibitor”ChEMBL 37, by rule

Other programs on PCSK9

ProgramCompanyFurthest phaseStudies
alirocumabruleSanofiphase 448
inclisiranruleNovartisphase 437
lerodalcibeprulelib-therapeutics-llcphase 314
tafolecimabruleInnovent Biologicsphase 38
recaticimabruleJiangsu HengRui Medicinephase 37
QLC7401ruleQilu Pharmaceuticalphase 35
SYH2053ruleCSPC Pharmaceutical Groupphase 35
SAL003ruleShenzhen Salubris Pharmaceuticalsphase 33
VERVE-102Eli Lillyphase 22
DNV001rulehangzhou-dinovate-biotech-co-ltdphase 21
RBD7022ruleQilu Pharmaceuticalphase 12

Studies

All 42 Amgen leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07803679Coronary Artery Disease4Not yet recruitingApr 30, 2029308
NCT07545226Healthy Participants · United States1CompletedSep 2, 2026405
NCT07422285Healthy Participants · United States1CompletedJul 24, 2026405
NCT05284747Cardiovascular Diseases · United States, Brazil, Sweden4Active, not recruitingMay 29, 20276,019
NCT03872401Coronary Disease · United States, Argentina, Australia and more3CompletedJul 25, 202512,301
NCT03570697Coronary Artery Disease · United States, Australia, Czechia and more3CompletedDec 18, 2020164
NCT03433755Hypercholesterolemia · China3TerminatedApr 24, 2020259
NCT03403374Hypercholesterolemia · India4CompletedNov 27, 201930
NCT03080935Dyslipidemias · Belgium, Denmark, France and more3TerminatedMar 4, 20221,600
NCT02867813Dyslipidemias · United States, Czechia, Hungary and more3CompletedMar 21, 20225,035
NCT02833844Dyslipidemias · United States, Australia, Belgium and more3CompletedJul 9, 2019467
NCT02739984Hypercholesterolemia · United States, Belgium, Canada and more3CompletedAug 3, 2017424
NCT02729025Dyslipidemias · United States, Canada, Netherlands3CompletedApr 5, 2018129
NCT02662569Diabetes Mellitus · United States, Argentina, Brazil and more3CompletedDec 6, 2017986
NCT02624869Hyperlipoproteinemia Type II · United States, Australia, Austria and more3CompletedJun 1, 2021163
NCT02585895Hypercholesterolemia · United States, Australia, Czechia and more3CompletedSep 1, 201639
NCT02392559Hypercholesterolemia · United States, Australia, Austria and more3CompletedNov 25, 2019158
NCT02304484Hypercholesterolemia · United States, Argentina, Australia and more3CompletedMar 9, 2018770
NCT02207634Dyslipidemias · United States, Australia, Belgium and more3CompletedNov 11, 20161,974
NCT02275156Hyperlipidemias · United States1CompletedDec 19, 201418
NCT02189837Hypercholesterolemia · Australia3CompletedFeb 13, 201589
NCT01984424Hyperlipidemias · United States, Australia, Canada and more3CompletedNov 10, 2015511
NCT01953328Hyperlipidemias · Japan3CompletedJun 2014409
NCT01879319Hypercholesterolemia · United States, Canada3CompletedNov 15, 2013164
NCT01854918Hyperlipidemias · United States, Australia, Austria and more3CompletedMay 31, 20183,681
NCT01849497Hypercholesterolemia · United States, Canada3CompletedSep 2, 2013149
NCT01813422Hypercholesterolemia · United States, Argentina, Australia and more3CompletedJul 12, 2016970
NCT01764633Dyslipidemias · United States, Argentina, Australia and more3CompletedNov 11, 201627,564
NCT01763918Hyperlipidemias · United States, Australia, Canada and more3CompletedNov 27, 2013331
NCT01763905Hyperlipidemias · United States, Australia, Belgium and more3CompletedNov 19, 2013307
NCT01763866Hyperlipidemias · United States, Australia, Belgium and more3CompletedNov 12, 20132,067
NCT01763827Hyperlipidemias · United States, Australia, Belgium and more3CompletedOct 10, 2013615
NCT01652703Hypercholesterolemia · Japan2CompletedMay 14, 2013310
NCT01624142Hyperlipoproteinemia Type II · United States, Australia, Belgium and more3CompletedMay 11, 2018300
NCT01588496Homozygous Familial Hypercholesterolemia · United States, Belgium, Canada and more3CompletedJan 31, 201458
NCT01516879Hypercholesterolemia · United States, Australia, Austria and more3CompletedOct 14, 2013905
NCT01439880Hypercholesterolemia · United States, Australia, Belgium and more2CompletedJun 20, 20181,324
NCT01380730Hyperlipidemias · United States, Canada, Czechia and more2CompletedApr 5, 2012631
NCT01375777Hyperlipidemias · United States, Australia, Belgium and more2CompletedMar 2, 2012411
NCT01375764Hyperlipidemias · United States, Australia, Belgium and more2CompletedMay 8, 2012160
NCT01375751Hyperlipoproteinemia Type II2CompletedMay 16, 2012168
NCT01133522Hyperlipidemias1CompletedSep 14, 201160

How it is read

Names in the registry

  • “Evolocumab”, 39 entries
  • “evolocumab”, 2 entries
  • “Evolocumab AI/pen”, 2 entries
  • “Evolocumab Drug Substance A (Test)”, 1 entry
  • “Evolocumab Drug Substance B (Reference)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.